Clinical Trial Update: LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients [Phase 2]

View source ↗

Summary

Phase 2 pharmacogenomic-driven study on pain management in oncology outpatients was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Tumor of Ill-defined Site

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Malignant Tumor of Ill-defined Site | Phase 2 | Status: TERMINATED | Results posted: 2021-02-02